|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-4-8
|
|
pubmed:abstractText |
The aim is to review briefly the problems related to treatment of drug-susceptible and drug-resistant tuberculosis (TB), describe recent advances in the development of new drugs and new regimens, and discuss implications for control programmes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1531-6971
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
186-93
|
|
pubmed:meshHeading |
pubmed-meshheading:20216421-Animals,
pubmed-meshheading:20216421-Antitubercular Agents,
pubmed-meshheading:20216421-Clinical Trials as Topic,
pubmed-meshheading:20216421-Drug Discovery,
pubmed-meshheading:20216421-Drug Evaluation, Preclinical,
pubmed-meshheading:20216421-Drug Industry,
pubmed-meshheading:20216421-Drug Therapy, Combination,
pubmed-meshheading:20216421-Female,
pubmed-meshheading:20216421-Fluoroquinolones,
pubmed-meshheading:20216421-Forecasting,
pubmed-meshheading:20216421-Humans,
pubmed-meshheading:20216421-Male,
pubmed-meshheading:20216421-Nitroimidazoles,
pubmed-meshheading:20216421-Rifamycins,
pubmed-meshheading:20216421-Tuberculosis, Multidrug-Resistant,
pubmed-meshheading:20216421-Tuberculosis, Pulmonary
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
|
|
pubmed:affiliation |
Stop TB Department and Stop TB Partnership, World Health Organization, Geneva, Switzerland. lienhardtc@who.int
|
|
pubmed:publicationType |
Journal Article,
Review
|
